Mining And Ores Tenders

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Permethrin, Atc P03ac04 for the Period 07/01/2023 - 06/30/2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Golimumab, Atc L04ab06 for the Period 07/01/2023 - 06/30/2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Lapatinib, Atc L01eh01 for the Period 07/01/2023 - 06/30/2025

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Substance Fusidic Acid/Betamethasone (Atc Code According to Who: D07cc01)

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Somatropin (H01ac01) as Part of a So-Called Open House Model.

Drugs with the Active Ingredient Combination Olodaterol and Tiotropium Bromide (Atc: R03al06)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Fremanezumab, Atc N02cd03 for the Period July 1St, 2023 - June 30Th, 2025

Completion of Non-exclusive Drug Discounts According to Section 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Fusidic Acid/betamethasone (atc Code According to Who: D07cc01)

Medicines Contracts with Accession Option

Drug Contracts with Option to Join